Abstract: Certain compounds, including 5,6-dihydro-3,9-dihydroxyindolo[2,1-a-isoquinolin12yl)[4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone and arzoxifen, are useful for providing protection to oligodendrocytes and neurons of multiple sclerosis patients.

Abstract: A method for the treatment of multiple sclerosis through the protection on the central nervous system neurons or oligodendrocytes which comprises administering to a patient having multiple sclerosis a therapeutically effective amount of a biphenyl compound as defined by formula I as follows: Wherein R1, R2, R3 and R4 are as defined herein

Abstract: Certain biphenyl compounds, including 5-chloro-6-(4-hydroxyphenyl)-2-naphthalenol and 6-(4-hydroxy-phenyl)-2-naphthalene methanol are useful in the treatment of multiple sclerosis on the cellular level of the central nervous system through the protection of the patients' oligodendrocytes and neurons.

Abstract: The invention provides a new use for certain SERM-like phenylnaphthyl compounds that do not exhibit affinity for alpha or beta type estrogen receptors (ER) in the treatment of multiple sclerosis.

Abstract: A novel neuroprotectant was identified by microarray analysis that is differentially expressed between the ventricular zone and the cortex of human adult and fetal brain. The secreted protein antagonizes Wnt action in Xenopus embryos. Methods are described for modulating free radical neurotoxicity by contacting cells with the protein, treating neuronal diseases associated with free radical-mediated cell death by administering the protein, determining neuroprotective genomic targets associated with select free radical toxicity pathways by screening with the protein and using the protein to identify other compounds that modulate the biological activity of the secreted protein and the cell machinery that reacts to the secreted protein.